AAV2/8-HLP-FVIII-V3

Phase 2Gene therapy

UUniversity College, London

AAV2/8-HLP-FVIII-V3 is one of 6 biologic programs targeting Haemophilia A. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Haemophilia aActive, not recruiting

Haemophilia aPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Haemophilia a

#DrugCompanyPhaseTrials

ALHEMO

Novo Nordisk

Phase 3

2 2

Efanesoctocog Alfa

Sanofi

Phase 3

1 3

Mim8

Novo Nordisk

Phase 3

2 4

Nuwiq

Octapharma

Phase 3

2 5

AAV2/8-HLP-FVIII-V3

UUniversity College, London

Phase 2

1 6

NNC0442-0344 a

Novo Nordisk

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Active, not recruiting

Haemophilia a

NCT03001830

Clinical

Trials by Indication[1]

Haemophilia A1 trial

Gene Therapy for Haemophilia A.

Active, not recruiting·UUniversity College, London·Phase 1/2·NCT03001830·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAV2/8-HLP-FVIII-V3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AAV2/8-HLP-FVIII-V3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AAV2/8-HLP-FVIII-V3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 2[1]
Company: UUniversity College, London

AAV2/8-HLP-FVIII-V3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Haemophilia A1 trial

References

Drug Info

Quick Facts

Related News